Plixorafenib Drug Asset Due Diligence Report 2026

This Plixorafenib Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 3 August 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Plixorafenib can convert its Small molecule drug profile and BRAF biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Plixorafenib (query alias: Plixorafenib)
Modality / target	Small molecule drug; BRAF; BRAF inhibitors
Highest global status	Phase 2
Originator	Daiichi Sankyo Co., Ltd.
Active developers	Fore Biotherapeutics, Inc., Plexxikon, Inc.

The MCP disease footprint includes BRAF mutation Solid Tumors, High grade glioma, Neoplasms. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT05503797	Phase 2	Recruiting	254	Objective Response Rate (ORR) (Subprotocols A, B and C)
NCT02428712	Phase 1/2	Completed	113	Area under the curve (AUC) of FORE8394
NCT06385119	Phase 1	Completed	28	Number of Participants With Treatment Emergent Adverse Events (TEAEs).

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A trial to evaluate CSF ctDNA and safety of plixorafenib alone or with retifanlimab in patients with BRAF-altered glioma.

Phase 1; n=20; evaluation: Positive. Reported fields: SD = 6.0 Pts

FORTE: A phase 2 master protocol assessing plixorafenib for BRAF-altered cancers<b></b>

Phase 2; n=100; evaluation: Positive. Reported fields: ORR(BICR) = 15.0 %

FORE Biotherapeutics Presents Phase 1/2a Plixorafenib Data Demonstrating Prolonged Duration of Effect in BRAF Altered Thyroid Cancers at American Thyroid Association® 2025 Annual Meeting

Phase 1/2; n=21; evaluation: Positive. Reported fields: -; -; -

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Plixorafenib addresses BRAF mutation Solid Tumors, High grade glioma, Neoplasms. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2020-06-03	Novellus to globally develop and commercialize Plexxikon's PLX-8394 for cancer.	Phase 1	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “BRAF gene fusions and uses thereof”. The milestone feed surfaced a patent-application signal described as “Methods and compositions for treatment of BRAF mutant cancers”. The milestone feed surfaced a patent-application signal described as “PLX-8394 or PLX-7904 for use in the treatment of BRAF-v600-related diseases”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO